Author

Alessandro Galbiati

AstraZeneca (United Kingdom)ORCID 0000-0002-8795-7934Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Alessandro Galbiati1 paper

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:protein structure· 1

Frequent Co-Authors

Alberto BoldriniiD· 1 shared Alexandros PatsilinakosiD· 1 shared Andrea AstolfiiD· 1 shared Anna Dominika StaniszewskaiD· 1 shared C. RisueñoiD· 1 shared Carlo SantambrogioiD· 1 shared Carmine VarricchioiD· 1 shared Cassiano LanginiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Alberto BoldriniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Protein Folding Interference Enables Selective Cyclin D1 Degradation

Alessandro Galbiati, Enrica Colasurdo, Alexandros Patsilinakos, Simone Lanfredini, Serena Bonifati, Tania Massignan, Carmine Varricchio, Leda Bencheva, Alberto Boldrini, Luca Terruzzi, Gianluca Papeo, Andrea Astolfi, Laura Raggi, Marta Pandini, Giulia Frapporti, , Giovanni Spagnolli

This paper identifies a folding intermediate of Cyclin D1 as a target for selective degradation, showing that pharmacological interference with this state inhibits tumor growth and overcomes resistance to CDK4/6 inhibitors.

bioRxiv · Oct 25, 2026 · PreprintBiochemistry

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

Giuditta Illuzzi, Alessandro Galbiati, Anna Dominika Staniszewska, Robert Hanson, Chrysiis Michaloglou, Sophie L. Cooke, Karolina Uznańska, Maja Białecka, Kamil J. Solarczyk, Harveer Dev, Charles E. Massie, Mark Robert Albertella, Elisabetta Leo, Josep V. Forment, Mark J. O’Connor

This study shows that combining androgen receptor inhibitors with PARP inhibitors enhances DNA damage in prostate cancer models, independent of BRCA mutations, by increasing double-strand breaks and micronuclei formation.

NAR Cancer · Oct 7, 2025Peer-reviewedCancer Biology